Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 1,453 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 1,453 shares of the stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $54.84, for a total transaction of $79,682.52. Following the sale, the chief operating officer now owns 196,594 shares in the company, valued at $10,781,214.96. This represents a 0.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jonathan Young also recently made the following trade(s):

• On Tuesday, June 10th, Jonathan Young sold 2,493 shares of Akero Therapeutics stock. The stock was sold at an average price of $53.99, for a total transaction of $134,597.07.

Akero Therapeutics Price Performance

Shares of NASDAQ:AKRO opened at $54.20 on Friday. The company has a market cap of $4.32 billion, a price-to-earnings ratio of -27.79 and a beta of -0.16. The company has a debt-to-equity ratio of 0.03, a current ratio of 16.80 and a quick ratio of 16.80. The firm has a 50 day simple moving average of $45.88 and a 200 day simple moving average of $41.17. Akero Therapeutics, Inc. has a one year low of $21.02 and a one year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings data on Monday, May 12th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of ($1.01) by $1.91. Research analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Citigroup reduced their price target on shares of Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Bank of America increased their price objective on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a “buy” rating in a research note on Tuesday, May 27th. HC Wainwright increased their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Monday, March 3rd. Finally, Morgan Stanley reissued an “overweight” rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $82.50.

Hedge Funds Weigh In On Akero Therapeutics

Large investors have recently modified their holdings of the business. Northwest & Ethical Investments L.P. bought a new position in shares of Akero Therapeutics during the first quarter valued at $32,000. GF Fund Management CO. LTD. bought a new position in shares of Akero Therapeutics during the fourth quarter valued at $41,000. Sterling Capital Management LLC raised its stake in shares of Akero Therapeutics by 764.3% during the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock valued at $50,000 after acquiring an additional 1,582 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Akero Therapeutics by 30.8% during the first quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company’s stock valued at $67,000 after acquiring an additional 390 shares during the last quarter. Finally, Quarry LP bought a new position in shares of Akero Therapeutics during the fourth quarter valued at $83,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.